Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A systematic review

Kasama Tejapira †, Tanat Yongpisarn †, Nawara Sakpuwadol ‡ and Poonkiat Suchonwanit *

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Background: Immune-mediated alopecias (IMAs), a group of hair disorders associated with immunological reactions, remain a therapeutic challenge since available treatments are generally unfavorable with potential side effects. Platelet-rich plasma (PRP) has been recently proposed as a treatment option based on several limited-quality studies; however, there is no systematic evaluation of PRP efficacy on IMAs in the literature.

Objective: To assess PRP’s effects in treating IMAs using a systematic review.

Methods: Electronic searches were conducted using PubMed, Embase, Scopus, and Cochrane Library databases. A search strategy was designed to retrieve all studies exploring PRP in treating IMAs, including alopecia areata (AA) and primary cicatricial alopecias (PCAs). In addition, all randomized and non-randomized studies reporting subjective and/or objective outcomes of alopecia treatment with PRP were included.

Results: Thirty-two studies were included, comprising 621 patients with AA and 19 patients with PCAs. PRP had superior efficacy as monotherapy in five studies, comparable to intralesional corticosteroids in six studies in AA treatment. In addition, in the analysis of PCAs, including lymphocytic and neutrophilic subtypes, PRP was efficacious in alleviating disease progression in nine studies.

Conclusion: PRP is considered a promising treatment for AA and PCAs in patients who experienced unfavorable outcomes from conventional treatment. However, its clinical application remains to be standardized, and its recommendation as a treatment for IMAs could not be ascertained due to a lack of high-quality evidence.

Systematic review registration: [https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=353859], identifier [CRD42022353859].

KEYWORDS
AA, immune-mediated alopecia, lichen planopilaris, LPP, non-scarring alopecia, PCA, scarring alopecia, hair loss
Introduction

Alopecia is a common dermatological disorder affecting the population worldwide. The condition is highly associated with psychological distress and impacts patients’ quality of life (1). Alopecia manifests varyingly and is categorized into non-cicatricial (non-scarring) and cicatricial (scarring) alopecias, which include several disorders (2). In non-cicatricial alopecia, hair follicle (HF) stem cells located in the bulge area are preserved with potential for regrowth. In contrast, they are irreversibly destroyed in the cicatricial subtype, leading to permanent alopecia (3, 4).

Immune-mediated alopecia (IMA) refers to hair loss disorders associated with immune responses involved in inflammation and autoimmunity to HFs. HF is an area of relative immune privilege. Several mechanisms, such as downregulating major histocompatibility complex (MHC) and expressing signals using type-1 transmembrane glycoprotein CD200, help protect HF from inflammatory insults (5, 6). Imbalances in the protective mechanism of HF, also called immune privilege collapse, are theorized to be the pathogenesis of IMAs (6–9).

Alopecia areata (AA) and primary cicatricial alopecias (PCAs) are two major subtypes of IMAs. AA is an autoimmune, non-scarring hair loss disorder histologically characterized by CD8+ and CD4+ T cells infiltrating the peribulbar area of anagen HFs (10–13). Because the inflammatory process of AA conserves stem cells, reversible hair loss can occur after AA subsides. In contrast, inflammation in PCAs mainly involves the hair bulge region, where HF stem cells locate, leading to the permanent destruction of HF and replacement with a scar (14–17). PCAs are classified based on the types of predominant inflammatory cell involvement into lymphocytic, neutrophilic, and mixed cell infiltrates (3).

Treatment modalities of IMAs aim to suppress the inflammatory response, prevent potential hair loss, and promote hair regrowth. Several therapeutic options have been introduced, such as topical and intralesional corticosteroids, systemic immunosuppressants, topical immunotherapy, lasers, and phototherapy, depending on IMA subtypes, degree of inflammation, disease stage, and relevant comorbidities (18–22). However, their therapeutic efficacy is still debated since treatment outcomes are generally unpredictable. Moreover, poor response, high recurrent rate, and potential side effects are frequently reported (23–25).

Recent advancements in understanding the pathogenesis of IMAs have accelerated the discovery of novel treatments. In recent years, the regenerative capability of platelet-rich plasma (PRP) has been used to treat several dermatological diseases. PRP is an autologous plasma preparation with concentrated platelet produced by centrifugation (26, 27). It comprises over 20 growth factors and cytokines, such as transforming growth factor (TGF), platelet-derived growth factors (PDGF), insulin-like growth factor (IGF), vascular endothelial growth factors (VEGF), epidermal growth factor (EGF), and fibroblast growth factor (FGF), playing a significant role in initiating tissue repair by releasing biologically active factors and immunomodulatory effect of innate and adaptive immune system (27–29).

Some studies have reported PRP’s efficacy in treating AA and PCAs with positive outcomes, with fewer side effects; others revealed the opposite. Given this inconclusive issue, it is essential to integrate and compare these findings in the secondary analysis. We aimed to assess PRP’s efficacy in treating AA and PCAs via a systematic review due to a lack of systematic evaluation of the therapeutic effects of PRP on IMAs.

Methods

Study design

The protocol was registered in PROSPERO (International Prospective Register of Systematic Reviews; no.CRD42022353859). The systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Electronic searches were conducted from the database’s inception to July 1, 2022, via PubMed, Embase, Scopus, and Cochrane Library databases. Using keywords and a controlled vocabulary, the search strategy was designed to retrieve all studies exploring PRP use in treating AA and PCAs. There were no restrictions on the language or publication period of the searches. Conference abstracts were excluded. Details of the search strategy are presented in Supplementary Table 1.

Study selection

Each article was reviewed independently by two reviewers (KT and TY). Disagreements were resolved via discussion with a third reviewer (NS). We included all randomized and non-randomized studies that reported any subjective and/or objective treatment outcomes.

Data extraction

Data were extracted from the included studies using a standardized format. The following data were collected: study type, study characteristics (authors, publication year, and study design), patient characteristics [diagnosis, number of patients, disease duration, previous treatment(s), and age], intervention(s), PRP protocol, investigations, objective and subjective assessment of hair growth, incidence of adverse effect(s), and follow-up duration. Corresponding investigators were contacted via email if there was missing data. Two independent reviewers extracted data (KT and TY), and discrepancies were resolved with the assistance of a third reviewer (NS).
Quality assessment

Quality assessment was performed using Rob-2 and ROBINS-1 for randomized and non-randomized studies, respectively (30, 31). Risk-of-bias plots were created using Risk-of-bias VISualization (robvis) (32).

Results

Study characteristics

After removing duplicates, 181 papers were screened by title and abstract. At the full-text stage, 87 full articles met our predefined selection criteria, and we further excluded 55 publications for the following reasons: review articles (n = 27), conference abstracts (n = 17), wrong population (n = 5), wrong intervention (n = 3), commentaries (n = 3), and secondary cicatricial alopecias (n = 2) (Figure 1). Thirty-two studies were included: 11 randomized controlled trials (RCTs) (33–43), 4 non-randomized studies (44–47), and 17 case series or case reports (48–64). Between 2013 and 2022, 23 AA studies (33–55) and nine PCA studies (56–64) were included, totaling 621 patients with AA and 19 with PCAs. Details of the included studies are summarized in Tables 1, 2.

Platelet-rich plasma protocols

The PRP preparation protocols of included studies are demonstrated in Tables 3, 4. Regarding the centrifugation method, there were 13 studies using single spin method (33, 34, 36, 39, 43, 47, 49, 52, 53, 58, 60, 63, 64), 10 using double spin method (35, 37, 38, 40–42, 45, 46, 51, 56), and eight provided no information (44, 48, 54, 55, 57, 59, 61, 62). Several types of PRP activators were used; seven studies used calcium chloride (37, 38, 41, 45, 46, 49, 60), four used calcium gluconate (33, 34, 36, 42), one used calcium carbonate (52), two did not use any activators (48, 53), and 17 provided no information (35, 39, 40, 43, 44, 47, 51, 54–59, 61–64). The most common ratio of activator to PRP applied by the included studies was 1:9.

Regarding treatment protocol, most studies used three or four treatment sessions, with 15 using three sessions (33, 38, 39, 40–42, 45, 47, 50, 53, 54, 56, 60, 63, 64), six using four sessions (35, 36, 39, 49, 57, 59), two treated until a satisfactory response was obtained (51, 61), and the remaining studies used different number of sessions. Our included studies selected different treatment intervals, with the most common interval being 4 weeks, selected by 17 studies (33, 34, 36, 39, 43, 47, 49, 51, 54–59, 61–64). The most common ratio of activator to PRP applied by the included studies was 1:9.

Regarding treatment protocol, most studies used three or four treatment sessions, with 15 using three sessions (33, 38, 39, 40–42, 45, 47, 50, 53, 54, 56, 60, 63, 64), six using four sessions (35, 36, 39, 49, 57, 59), two treated until a satisfactory response was obtained (51, 61), and the remaining studies used different number of sessions. Our included studies selected different treatment intervals, with the most common interval being 4 weeks, selected by 17 studies (33, 34, 36, 39, 40–42, 44, 45, 47, 51, 55, 56, 58, 60, 62, 64); five studies selected 3 weeks (35, 39, 50, 57, 59), four selected 2 weeks (37, 46, 49, 52), one
### TABLE 1 Characteristics of alopecia areata studies included in the systematic review.

| References           | Characteristic of enrolled subjects | Intervention | Objective measures | Objective assessment of hair growth | Subjective assessment of hair growth | Adverse effects | Follow up time |
|----------------------|-------------------------------------|--------------|--------------------|-------------------------------------|---------------------------------------|----------------|----------------|
| Trink et al. (33)    | Forty-five patients with chronic, recurring AA of at least 2 years duration, symmetrically distributed 4–6 patches of hair loss, 20 (44.44%) male, 25 (55.56%) female, mean age 28 years | • PRP injection | • SALT score reduction | Trichoscopic exam | • 96% of PRP group, 25% of TA group had fully pigmented hair from the beginning of hair regrowth | SALT score | NR | 52 weeks |
|                      |                                    | • TA injection (2.5 mg/ml) | • Hair regrowth | • Both PRP and TA groups decreased the number of dystrophic hairs, but PRP led to significantly better dermoscopy results compared with TA treatment | | | |
|                      |                                    | • Placebo | • Trichoscopic evaluation (exclamation-mark hairs, black dots, yellow dots, and pigtail regrowing hair) | | | | |
|                      |                                    | | • Itching/burning sensation | | | | |
|                      |                                    | | • Disease relapse | | | | |
|                      |                                    | | • Ki-67 IHC staining | | | | |
|                      |                                    | | | | | | |
| El Taieb et al. (34) | Ninety patients with AA any severity, 49 (54.44%) male, 51 (55.67%) female mean age 24.29 ± 9.05 years | • PRP injection | • Hair regrowth | Dermoscopic exam | | | |
|                      |                                    | • Topical 5% minoxidil | | | | | |
|                      |                                    | • Placebo | • Dermaloscopic exam (short vellus hair, yellow dots) | | | | |
|                      |                                    | | | | | | |
| Nagaratna et al. (35)| Twenty-five AA patients with disease duration more than 24 weeks, Male:female 1:2.71, mean age 33.43 ± 7.22 years | • PRP | • SALT score | Dermoscopic exam | | | |
|                      |                                    | | | | | | |
|                      |                                    | • No control reported | • Hair regrowth score | | | | |
|                      |                                    | | | | | | |
| Khademi et al. (36) | Ten patients with AT for at least 3 years, 5 (50%) men, 5 (50%) women, mean age 28.90 ± 6.28 years | • PRP | • SALT score | Dermoscopic exam | | | |
|                      |                                    | | | | | | |
|                      |                                    | • NSS | • Hair regrowth | | | | |
|                      |                                    | | | | | | |
| Albalat and Ebrahim (37) | Eighty patients with chronic recurring AA 62/80 (77.5%) had < 25% scalp area involvement, 68 (85%) male, 12 (15%) female, mean age 34.29 ± 9.226 years | • PRP | • SALT score (in 6-point score, 50 = no alopecia – 55 = alopecia totalis) | Dermoscopic | | | |
|                      |                                    | • TA (5 mg/ml) | • Hair regrowth score | photomicrograph | | | |
|                      |                                    | | • Dermoscopic | | | | |
|                      |                                    | | photomicrograph | | | | |
|                      |                                    | | • Recurrence | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
|                      |                                    | | | | | | |
| References          | Characteristic of enrolled subjects                                      | Intervention                        | Objective measures                                | Objective assessment of hair growth                                                                 | Subjective assessment of hair growth | Adverse effects                                                                 | Follow up time |
|--------------------|---------------------------------------------------------------------------|-------------------------------------|--------------------------------------------------|----------------------------------------------------------------------------------------------------|------------------------------------|--------------------------------------------------------------------------------|----------------|
| Ragab et al. (38)  | Sixty patients with AA (excluded AT and AU), 48 (80%) male, 12 (20%) female, mean age 32.2 ± 13.098 years | • Intradermal PRP  
• PRP with FCL  
• PRP with micro needling | • Percentage of SALT score reduction  
• Patient satisfaction  
• Pain severity in visual analogue scale | NR                                                                 | SALT score reduction and patient satisfaction  
• No significant difference in the degree of improvement between the groups studied at the end of the sessions by physicians’ clinical assessment ($p = 0.268$) or by patient satisfaction ($p = 0.147$) | • Pain during the session was more obvious in intradermal injection > FCL > micro needling | 24 weeks |
| Kapoor et al. (39) | Forty patients with Patchy AA on scalp with < 25% area involvement, 28/40 (70%) disease duration < 6mo, 18 (45%) male, 22 (55%) female. mean age 27.1 ± 7.07 years | • PRP  
• TA (10 mg/ml) | • Percentage of SALT score reduction  
• Pain severity in visual analogue scale  
• Disease relapse | NR                                                                 | Percentage of SALT score reduction  
• Reduction in SALT score at each visit with respect to baseline was greater in the TA group (11/20 (55%) patient gained > 50% SALT score reduction) as compared to PRP group Disease relapse  
• At 24 weeks after beginning of treatment 1/20 (5%) in TA group and 2/20 (10%) in PRP group got disease relapse | • The pain VAS score was statistically significant higher in PRP group (25.6 ± 10.65 vs. 2.25 ± 3.27) | 24 weeks |
| Hegde et al. (40)  | Fifty patients with patchy AA at scalp, age 18–60 years                  | • PRP  
• Intralesional TA (10 mg/ml)  
• Placebo | • Percentage of SALT score reduction  
• Percentage change in dystrophic hair (assess in one representative alopecic patch between 12 and 3'O clock position)  
• Hair regrowth | Percentage change in dystrophic hair  
• No statistical significance improvement in dermoscopic findings between PRP and TA ($p = 0.448$) nor PRP and placebo ($p = 0.448$) | Percentage of SALT score reduction  
• Statistically significant declined in mean SALT score was observed in all three groups by the end of 8 weeks ($p < 0.001$) Hair regrowth  
• Statistically significant absolute growth and percentage regrowth were observed maximally in TA > PRP > placebo ($p = 0.016$ and 0.0108)  
• Near complete regrowth after 3 session was observed in 11 (44%) of PRP-treated group and 30 (40%) of TA-treated group | • Pain during injection was observed in 18 (27%) of PRP-treated group and 3 (20%) of TA-treated group ($p < 0.05$) | 20 weeks |
| Balakrishnan et al. (41) | Forty patients with patchy AA confined only at scalp majority of patients had single patch, 69% of patients had disease duration < 12 weeks, 27 (67.5%) male, 13 (32.5%) female, age ≥ 18 years | • PRP  
• Intralesional TA (10 mg/ml) | • SALT score reduction  
• Hair regrowth scale (patient assessment) | NR                                                                 | SALT score reduction  
• At 8 weeks, significant difference in the score reduction in PRP > TA group ($p = 0.028$)  
• At 12 weeks, no statistically significant difference between two groups Hair regrowth  
• No statistically significant difference in hair regrowth between PRP (excellent 12.5%, good 31.5%) and TA-treated group (excellent none, good 18.8%) | • No side effect was reported in intralesional TA group  
• 3/20 (15%) patients in PRP-treated site and RP group reported severe pain during injection | 12 weeks |

(Continued)
### TABLE 1 (Continued)

| References          | Characteristic of enrolled subjects | Intervention | Objective measures | Objective assessment of hair growth | Subjective assessment of hair growth | Adverse effects | Follow up time |
|---------------------|-------------------------------------|--------------|--------------------|-------------------------------------|--------------------------------------|-----------------|----------------|
| Gupta et al. (42)   | Twenty-seven AA patients with SALT score ≥ 25%, mean disease duration 6 years or longer, 13 (48.14%) male, 14 (51.85%) female, mean age 23.89 ± 4.64 years | • PRP  
• NSS (placebo) | • Percentage of SALT score reduction  
• Percent reduction of dystrophic hair  
• LIKERT score on hair regrowth  
• Patient global assessment score  
• Biopsy with IHC at PRP injected site | Dermoscopic evaluation  
• 9 (64.3%) PRP-treated site and 10 (66.7%) placebo-treated site showed ≥ 50% reduction in dystrophic hair marker  
• In PRP treated site, lesional T helper, T reg cytokine mRNA expression mean interferon gamma (p = 0.001), IL-17 (p = 0.009) mRNA expression decreased significantly and mean IL-10 (p = 0.049) FOXP3 (p = 0.011) mRNA expression increased significantly | Physician subjective  
• Significant difference in percent SALT score reduction at 20th week between PRP (9.05 ± 36.48%) and placebo (4.99 ± 33.88%) treated area  
• 6/27 (22.22%) patients had comparable hair regrowth in PRP-treated and placebo-treated 9/27 (33.33%) better response on PRP site, 5/27 (11.11%) better response on placebo site, 4/27 (14.81%) no hair regrowth in either site  
• Patient global assessment  
• 3 (21%) in PRP treated site and 2 (7.4%) in placebo-treated site were reported ≥ 50% improvement | 23/37 (85.2%) reported pain on injected site after procedure, resolved in 2–5 days | 20 weeks |
| Tawfik et al. (43)  | Thirty patients with chronic recurrent AA for a period of 2 years, resistant to other lines of treatment, 26 (86.67%) male, 4 (13.33%) females, mean age 28.8 ± 6.8 years | • PRP  
• LLLT 3 times weekly  
• NSS (placebo) | • Hair growth by digital photograph  
• Hair density and hair diameter by fototrichogram  
• Patient satisfaction 12 weeks after last session | Hair density and diameter  
• PRP patches showed significant improvement in hair density (p = 0.007) and hair thickness (p = 0.002)  
• LLLT patches showed significant improvement in hair density only (p = 0.02)  
• None of patches in placebo group showed significant increase in hair density and thickness | Hair growth  
• 11 (44%) PRP patches and 8 (32%) LLLT patches showed more than 75% improvement in hair coverage  
• 10 (40%) PRP patches and 11 (44%) in LLLT patches  
• Patient satisfaction  
• Maximum degree of contentment was reported at PRP-treated area | Temporary pain in PRP-treated sites  
• 5/25 (20%) patients reported scalp tenderness after LLLT, resolved within 2 h | 18 weeks |
| Non-randomized studies | Singh (44) Twenty patients with patches AA with disease duration at least 2 years, age 25–35 years | • PRP | • Disease relapse | 1 patient had relapse disease | NR | No adverse event | 52 weeks |
|                     | Khan et al. (45) Twenty patients with patches of alopecia duration at least 24 weeks, 12 (60%) male, 8 (40%) female, age 16–50 years | • PRP  
• Hair regrowth  
• Disease relapse | • Relapse did not occur in any patient | Hair regrowth  
• 6/20 (30%) patients (4 female and 2 male) had excellent response  
• 5/20 (25%) patients (4 male and 1 female) with good response  
• 4/20 (20%) patients (2 male and 2 female) showed hair response  
• 5/20 (25%) (4 male and 1 female) poor response  
• Significant hair growth was seen after 8 weeks of PRP treatment | 10/20 (50%) reported mild pain within 30 min at site of injection  
• No other side effects were reported by any of the patients | Mild pain was noted for 5–30 min at site of injection  
• No other side effects were noted nor reported by any of the patients | 36 weeks |
| References                  | Characteristic of enrolled subjects                                                                 | Intervention                  | Objective measures                                     | Objective assessment of hair growth                                                                 | Subjective assessment of hair growth                                                                 | Adverse effects                                                                 | Follow up time |
|-----------------------------|------------------------------------------------------------------------------------------------------|------------------------------|--------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|----------------|
| Fayed et al. (46)           | Forty-one patients with AA disease duration less than 24 weeks, 32 (78.04%) male, 9 (21.95%) female, Mean age 26.68 ± 4.49 years | • PRP injection            | • SALT score change                                   | • SALT score                                                                                       | • Decrease > 50% in 13 (31.7%) PRP, 2 (4.9%) placebo and statistically significant difference between treatment side and placebo side (p = 0.002) | • Grade1 (S1) showed the best improvement 12/23 (52.3%)                          | 20 weeks        |
|                             |                                                                                                     | • NSS injection            | Divided patients into four groups (S1 = 25% hair loss  S2 = 25–49% hair loss  S3 = 50–74% hair loss  S4 = 75–99% hair loss) |                                                                                                     |                                                                                                     | • Grade2 (S2) 1/7 (14.3%) had hair regrowth                                       |                                                                                   |
|                             |                                                                                                     |                              | • DQOL questionnaire                                   |                                                                                                     | • No response in grade 3–4                                                                       | • 15 (36.6%) suffered a very large effect, after treatment became 6 (14.6%), 12 (29.3%) had moderate degree, after treatment became 7 (17.1%), 12 (29.3%) mild degree, became after treatment 11 (26.8%) |                                                                                   |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     | • 15 (36.6%) suffered a very large effect, after treatment became 6 (14.6%), 12 (29.3%) had moderate degree, after treatment became 7 (17.1%), 12 (29.3%) mild degree, became after treatment 11 (26.8%) |                                                                                   |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     | • NR                                                                                               | • 31 (75.6%) tolerable pain duration no more than 30 min                         |                                                                                   |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     | • 6 (14.6%) tenderness, burning sensation                                                         | • 100% erythema at injection site for few hours                                   |                                                                                   |
| Fawzy et al. (47)           | Thirty-one patients with AA disease duration less than 24 weeks, 23 (74.19%) male, 8 (25.80%) female, Mean age 32.67 ± 11.30 years | • PRP injection            | • SALT score reduction                                  | • Trichoscopic exam                                                                                  | Statistically significant improvement in trichoscopic findings at final evaluation when compared to baseline in both group A and B | SALT score reduction                                                                 | NR             |
|                             |                                                                                                     | • TA injection (5 mg/ml)    |                                                                                                       |                                                                                                     |                                                                                                     |                                                                                   | 12 weeks        |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     |                                                                                                     |                                                                                   |
| Case series/case reports    |                                                                                                     |                              |                                                                                                       |                                                                                                     |                                                                                                     |                                                                                   |
| Donovan (48)                | A 41-year-old female with ophiasis AA and bipolar disorder                                         | Intralesimal PRP           | Hair regrowth                                           |                                                                                                     |                                                                                                     | Hair regrowth                                                                    | 12 weeks        |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     |                                                                                                     | • Hair regrowth was noted by 4 weeks with robust regrowth of hair measuring 2.8 cm by 12 weeks |                                                                                   |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     |                                                                                                     | • Mild tender on day of the procedure and 2 following days                         |                                                                                   |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     |                                                                                                     | NR                                                                              |                                                                                   |
| Mubki (49)                  | A 22-year-old female with chronic diffuse AA for 5 years                                           | Left half intralesimal TA  (2.5 mg/ml)                                          | Hair regrowth                                           | Hair coverage                                                                                       |                                                                                                     | Hair density                                                                    | NR             |
|                             |                                                                                                     | Right half 4 PRP treatment sessions were alternated with 4 TA treatment sessions at 2 weeks intervals |                                                                                                       |                                                                                                     |                                                                                                     | • Both treatment modalities; right half and left half resulted in an increase in the number of terminal hairs as compared to the baseline (16 and 12%, respectively) | 18 weeks        |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     |                                                                                                     | • Hair diameter                                                                  |                                                                                   |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     |                                                                                                     | Only the right half showed an increase in the mean hair shaft diameter (+35%) compared to a decline by (−4%) in the left half |                                                                                   |
|                             |                                                                                                     |                              |                                                                                                       |                                                                                                     |                                                                                                     |                                                                                   | (Continued)
| References                        | Characteristic of enrolled subjects                                                                 | Intervention                  | Objective measures                                                                 | Objective assessment of hair growth                        | Subjective assessment of hair growth                                                                 | Adverse effects                                                                 | Follow up time |
|----------------------------------|------------------------------------------------------------------------------------------------------|-------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|----------------|
| De Vasconcelos et al. (50)       | A 43-year-old female with AA for 1 year                                                              | PRP injection                | • Hair regrowth                                                                   | NR                                                        | • At the end of the three sessions, hair regrowth was observed in the clinical and dermoscopic exams    | NR                                                             | 9 weeks        |
| Fonseka et al. (51)              | • A 25-year-old female with AA<br>• A 23-year-old female with AT<br>• A 55-year-old female with AT    | PRP injection with 5% minoxidil lotion and topical steroid | • Hair regrowth                                                                   | NR                                                        | At the end of the third session, case 1 had marked response with approximately 80% recovery of scalp hair growth<br>• Case 2 and case 3 demonstrated almost complete recovery of scalp hair growth after 6 and 8 sessions, respectively | No adverse effect                                                             | 32 weeks       |
| Chhabra and Verma (52)           | A 11-year-old boy with AT with disease duration 1 year (scalp and eyebrow involvement)              | Apremilast 10 mg twice daily for initial 10 days and the dose was increased to 30 mg morning 10 mg evening from 11th day onward with PRP injection | • Hair regrowth                                                                   | NR                                                        | Hair began to regrow between 4 and 6 weeks of the therapy<br>• Apremilast and PRP were continued and at the end of 24 weeks robust hair growth was observed over the scalp and eyebrows except an ophiasic patch over the right temporal region which showed hair growth at 32 weeks | Mild tenderness and erythema of transient nature                             | 32 weeks       |
| Pototschnig and Madl (53)        | A 30-year-old man with AA barbae, disease duration over 2 years                                      | Intralesional PRP            | • Hair regrowth                                                                   | NR                                                        | First follow up (before 2nd injection) disease was stabilized and at 1 year follow up robust regrowth was observed | Minimal discomfort within the first 36 h after injection                      | 52 weeks       |
| Ekelem et al. (54)               | • A 60-year-old woman with patchy AA<br>• A 69-year-old female with AU<br>• A 58-year-old female with AA and FFA | Intralesional PRP            | • In-line fiber-based swept-source OCT system (Thorlabs, Newton, NJ, USA)<br>• Hair regrowth | In-line fiber-based swept-source OCT system<br>• Increased in follicular unit count by week 24 in all cases | Case 1 marked clinical improvement by week 12, which was maintained or improved by week 24<br>• Case 2 no clinical improvement<br>• Case 3 worsening at week 12 and improved by week 24 | NR                                                             | 24 weeks       |
| Ederaine et al. (55)             | A 31-year-old woman with AU and plaque psoriasis                                                     | Intralesional PRP with oral tofacitinb | • Hair regrowth                                                                   | NR                                                        | Hair regrowth<br>• Significant regrowth was noted after 16 weeks of adjunctive PRP therapy | Localized pain but no major toxicities                                             | 40 weeks       |

AA, alopecia areata; AT, alopecia totalis; AU, alopecia universalis; FCL, fractional CO₂ laser; FFA, frontal fibrosing alopecia; FOXP, forkhead box P3; IHC, immunohistochemistry; IL, interleukin; LLLT, low level laser therapy; NR, not reported; NSS, normal saline solution; PRP, platelet-rich plasma; SALT, severity of alopecia tool; TA, triamcinolone acetonide.
| References            | Participant | Treatment | Outcome measurement | Primary outcome | Adverse effects | Duration of follow up |
|-----------------------|-------------|-----------|---------------------|-----------------|----------------|----------------------|
| Case series/case reports |             |           |                     |                 |                |                      |
| Bolanča et al. (56)   | A 25-year-old female with LPP | Intradermal PRP injection 3 ml 4 weeks apart for 3 sessions | Not specified | • Completed regression of itching and hair shading, no perifollicular erythema and perifollicular scaling on the trichoscopy | NR | NR |
| Jha (57)              | Two patients with LPP (Therapeutic pearl) | Intradermal PRP injection 3 weeks apart for 4 sessions | Not specified | • Significant hair thickening | NR | NR |
| Özcan et al. (58)     | A 44-year-old female with FFA | Intradermal PRP injection 0.1 ml/cm2 4 weeks apart for 5 sessions in addition to TA injection, oral hydroxychloroquine, and topical minoxidil | Not specified | • After 4 weeks, perifollicular erythema, scaling, and lichenoid papules on the frontotemporal hairline were improved, and no further hair loss was noted after 20 weeks | NR | 20 weeks |
| Jha (59)              | One patient with LPP (Therapeutic pearl) | Intradermal PRP injection 3 weeks apart for 4 sessions with topical 2% minoxidil | Not specified | • Significant hair thickening | NR | NR |
| Dina and Aguh (60)    | A 53-year-old woman CCCA with AGA | Intradermal PRP injection 4–4.2 ml 4 weeks apart for 3 sessions | Follicular density at hairline | • Greater than 50% improvement in hair density along hairline | NR | NR |
| Svidos et al. (61)    | Ten patients with FFA, FAPD, LPP 3 (30%) male, 7 (70%) female mean age 57.4 ± 15.84 years | Four PRP treatment sessions as an adjunctive therapy | Hairline measurements from fixed points | • Global improvement in hair density | NR | NR |
| Suh et al. (62)       | A 36-year-old man with folliculitis delcavans | Intralacional PRP combined with intralacional TA at 5–6 weeks interval and oral doxycycline | Not specified | • Significant hair regrowth was observed | NR | NR |
| Polster et al. (63)   | A 48-year-old patient with SLE and DLE presented with scarring alopecia | Intralacional PRP | Hair regrowth | • Normal hair growth was observed | NR | NR |
| Klein et al. (64)     | A 46-year-old woman with biopsy proven LPP resisted to conventional treatment | Intralacional PRP with oral naltrexone | Hair density | • Global improvement in hair density | NR | NR |

AGA, androgenic alopecia; CCCA, central centrifugal cicatricial alopecia; DLE, discoid lupus erythematosus; FAPD, fibrosing alopecia in a pattern distribution; FFA, frontal fibrosing alopecia; LPP, lichen planopilaris; NR, not reported; PRP, platelet-rich plasma; SLE, systemic lupus erythematosus; TA, triamcinolone acetonide.

selected 1 week (43), and four selected interval of ≥ 6 weeks (53, 54, 62, 63).

Efficacy of platelet-rich plasma for alopecia areata

Platelet-rich plasma monotherapy for alopecia areata

Several studies have demonstrated hair regrowth in AA lesions after PRP monotherapy. Among studies included, PRP showed superior efficacy compared to placebo in Severity of Alopecia Tool (SALT) score reduction (35, 42, 46), hair regrowth (35, 42, 45), and decrease in dystrophic hairs (42, 54), in mild cases of AA regardless of disease duration. For more severe AA cases, Khademi et al. found that PRP as monotherapy was relatively ineffective in alopecia totalis (AT) (36). Regarding different delivery methods of PRP, Ragab et al. reported that the efficacy of PRP in SALT score reduction was comparable among intradermal injection, fractional CO2 laser, and microneedling. At the end of the study, no significant difference between the groups was observed in physician clinical assessment and patient satisfaction (38).

Platelet-rich plasma compared with other treatments for alopecia areata

Clinical trials were conducted to compare PRP with intralacional triamcinolone acetonide (TA). PRP was found to be effective in improving hair density and reducing dystrophic hairs compared to TA. However, the duration of follow-up varied across studies, with some showing improvement within 3–4 sessions and others reporting sustained improvement with longer follow-up periods.
| References            | No. of session | Interval | Max F/U | Route of application                                      | Protocol/rpm or G—centrifuged time | Activator                                      | Blood volume/PRP volume |
|-----------------------|----------------|----------|---------|-----------------------------------------------------------|-------------------------------------|-----------------------------------------------|-------------------------|
| **Randomized control studies** |                |          |         |                                                           |                                     |                                               |                         |
| Trink et al. (33)     | 3              | 4 weeks  | 52 weeks| Intralesional injected                                   | Single spin method ● 70 G–8 min    | Calcium gluconate                             | 36 ml/NR                |
| El Taieb et al. (34)  | 3              | 4 weeks  | 12 weeks| Intralesional injection                                  | Single spin method ● 3000 rpm–10 min| Calcium gluconate                             | 10/4 ml                 |
| Nagaratna et al. (35) | 4              | 3 weeks  | 36 weeks| Microneedling using a dermaroller then intermittent application of PRP| Double spin method ● 3000 rpm–15 min ● 2000 rpm–10 min| NR                                             | 8/5 ml                  |
| Khamemi et al. (36)   | 4              | 4 weeks  | 16 weeks| Intralesional injection (0.1 ml/1.5–2 cm²)              | Single spin method ● 3500 rpm–5 min | Calcium gluconate ● Calcium bicarbonate (0.1 ml per PRP 4 ml) | 8/4 ml                  |
| Albalat and Ebrahim (37) | 3–5            | 2 weeks  | 24 weeks| Intralesional injection (0.1 ml/cm²)                     | Double spin method ● 150 G–10 min ● 1500–2000 G–10 min | CaCl₂ (0.1 ml of CaCl₂ per 0.9 ml of PRP)       | 15/3 ml                 |
| Ragab et al. (38)     | 3              | 4 weeks  | 24 weeks| Group A: Intralesional PRP injection ● Group B: FCL followed by topical PRP ● Group C: microneedling by dermalroller (1.5 mm needles) followed by topical PRP | Double spin method ● 1000 rpm–15 min ● 4000 rpm–10 min | 3% CaCl₂ (0.1 ml for each 1 ml of PRP)           | 10 ml/NR                |
| Kapoor et al. (39)    | 4              | 3 weeks  | 24 weeks| Intralesional injection (0.1 ml/cm²)                     | Single spin method/2000 rpm–3 min   | NR                                            | 20 ml/NR                |
| Hegde et al. (40)     | 3              | 4 weeks  | 20 weeks| Intralesional injection (0.1 ml/cm²)                     | Double spin method ● 1400 rpm–10 min ● 2800 rpm–10 min | NR                                            | 8.5 ml/NR               |
| Balakrishnan et al. (41) | 3              | 4 weeks  | 12 weeks| Intralesional injected 45° angle (0.1 ml/cm²)            | Double spin method ● 1500 rpm–15 min ● 2500 rpm–10 min | CaCl₂ (add CaCl₂ 0.1 ml per 0.9 ml of PRP)       | 15/3 ml                 |
| Gupta et al. (42)     | 3              | 4 weeks  | 20 weeks| Intralesional injection (0.1 ml/cm²)                     | Manual double spin method ● 160 G–10 min ● 400 G–10 min | Calcium gluconate (1:9 ratio)                  | 40/4–5 ml               |
| Tawfik et al. (43)    | 6              | 1 week   | 18 weeks| Intralesional injection                                  | Single spin method/3500 rpm–10 min  | NR                                            | 10/5 ml                 |
| **Non-randomized studies** |                |          |         |                                                           |                                     |                                               |                         |
| Singh (44)            | 6              | 4 weeks  | 52 weeks| Intralesional injection                                  | NR                                  | 10% CaCl₂ (0.3 ml for 1 ml of PRP)             | 25 ml/NR                |
| Khan et al. (45)      | 3              | 4 weeks  | 36 weeks| Intralesional injection (0.1 ml/cm² at a site 1 cm apart)| Takikawa’s manual double spin method with slight modification ● 2000 rpm–10 min ● 4000 rpm–10 min | NR                                            | 15 ml/NR                |
| Fayed et al. (46)     | Ten or shorter if hair regrowth occurred | 2 weeks  | 20 weeks| Intralesional injection (20 mm apart)                   | Double spin method ● 3000 rpm–7 min ● 4000 rpm–5 min | CaCl₂                                      | 10–30 ml/NR             |
| Fawzy et al. (47)     | 3              | 4 weeks  | 12 weeks| Intralesional injection (0.1 ml/cm²)                     | Single spin method ● 3000 rpm–10 min | NR                                            | 10/2–3 ml               |

(Continued)
### References

| Case series/Case reports | No. of session | Interval | Max F/U | Route of application | Blood volume/PRP volume | Activator | Protocol/number of G–centrifuged time | Reference |
|--------------------------|----------------|----------|---------|----------------------|-------------------------|-----------|------------------------------------|-----------|
| Donovan (48)             | 1              | 12 weeks | NR      | Intralesional injection | 120/9 ml               | Not used  | Double spin method • 1500 G–4 min |          |
| Mubki (49)               | 4              | 2 weeks | 18 weeks | Intralesional injection (0.1 ml/cm²) | NR | NR | Single spin method • 18 ml/NR |          |
| De Vasconcelos et al. (50) | 3              | 3 weeks | 9 weeks  | Intralesional injection (1 cm apart) | NR | NR | Double spin method • 3000 rpm–10 min |          |
| Fonseka et al. (51)      | Until satisfactory response was obtained | 4 weeks | 32 weeks | Intralesional injection (2 cm apart) | NR | NR | Single spin method • 3000 rpm–5 min |          |
| Chhabra and Verma (52)   | NR             | 2 weeks | 4 weeks  | Intralesional injection (0 ml/cm²) | NR | Calcium carbonate 0.1 ml | Double spin method • 350 G–5 min |          |
| Pototschnig and Madl (53)| 3              | 6 weeks | 52 weeks | Intralesional injection (1 cm apart at a depth of ≥2 mm) | NR | NR | Not used |          |
| Ekelem et al. (54)       | NR             | 6 weeks | 24 weeks | NR | NR | NR | NR |          |
| Ederaine et al. (55)     | NR             | 4 weeks | 40 weeks | Intralesional injection (0 ml/cm²) | NR | NR | NR |          |

G, gravitational force; NR, not reported; PRP, platelet rich plasma; rpm, revolutions per minute.

to be non-inferior to intralesional TA, a standard treatment for patchy AA. Trink et al. compared PRP to 2.5 mg/ml intralesional TA and found that PRP therapy resulted in a greater reduction in SALT score and improved dermoscopic features and relapse rates (33). According to studies comparing higher TA concentrations (10 mg/ml) with PRP in which most patients had patchy AA with < 25% scalp involvement or < 6 months of disease duration, each treatment had comparable efficacy (37, 39–41, 47). However, according to a few studies, TA-treated groups demonstrated a greater reduction in SALT score and greater hair regrowth (39, 40). Two studies found that the PRP group had a lower relapse rate than the corticosteroid group (33, 37). Efficacy of PRP in AA has also been compared to topical minoxidil and low-level laser therapy (LLLT). PRP showed superior to 5% topical minoxidil in improving dystrophic hair and had a greater effect on improving hair diameter compared to LLLT (34, 43).

### Platelet-rich plasma as an adjunctive treatment for alopecia areata

Studies investigating PRP as a co-intervention for AA are limited. Mubki reported an increased hair diameter in combined PRP and TA injected scalp side compared to a decline in the contralateral side in a 22-year-old female with chronic diffuse AA for 5 years (49). Two case reports published in 2019 reported some efficacy of PRP as adjuvant therapy on hair regrowth in AT patients (51, 52). Of the two studies, one study initiated PRP as adjuvant therapy after a 7-month course of Janus kinase inhibitor (JAKi) treatment in an 11-year-old patient with AT (52), and another study added PRP as an adjuvant to topical corticosteroids and minoxidil (51). In addition, Ederaine et al. reported an adjuvant effect of PRP with JAKi, showing significant hair regrowth after 4 months of combined treatment in a 31-year-old woman with plaque psoriasis who presented with patchy AA progressed to alopecia universalis (AU) (55).

### Efficacy of platelet-rich plasma for primary cicatricial alopecias

There are only a few studies that documented the efficacy of PRP in PCAs to date. In our review, six case reports and three case series addressed the efficacy of PRP in hair regrowth, reduction of clinical itching and scaling, and improvement of dermoscopic features (perifollicular erythema and scaling) after an average of three PRP sessions (56–64). Among them, two case series demonstrated a more reliable perspective of PRP efficacy. One case series comprising 10 patients showed variable treatment responses depending on patients’ characteristics (61), and another, comprising two patients, indicated decreasing efficacy of PRP treatment over time (60). Patients in included studies had lymphocytic (i.e., lichen planopilaris, frontal fibrosing alopecia, fibrosing alopecia in a patern distribution,
TABLE 4 Platelet-rich plasma preparation protocols of included primary cicatricial alopecia studies.

| References          | No. of session | Interval | Max F/U | Route of application | Protocol/rpm or G Activator Blood volume/PRP volume |
|---------------------|----------------|----------|---------|----------------------|--------------------------------------------------|
| **Case series/case reports** |                |          |         |                      |                                                  |
| Bolanča et al. (56) | 3              | 4 weeks  | 12 weeks| Intralesional injection | Double spin method<br>• 500 G–10 min<br>• 1520 G–10 min | NR 15/3 ml |
| Jha (57)           | 4              | 3 weeks  | 12 weeks| Intralesional injection | NR | NR/NR |
| Özcan et al. (58)  | 5              | 4 weeks  | 20 weeks| Intralesional injection<br>(0.1 ml/cm²) | Single spin method<br>• 4000 rpm–10 min | NR 14 ml/NR |
| Jha (59)           | 4              | 3 weeks  | 12 weeks| Intralesional injection | NR | NR/NR |
| Dina and Aguh (60) | 3              | 4 weeks  | 12 weeks| NR | Single spin method<br>• 1100 G–6 min | 0.5-M CaCl² 9/4–4.2 ml |
| Svigos et al. (61) | 3              | 4 weeks  | 12 weeks| NR | Single spin method<br>• 1100 G–6 min | 0.5-M CaCl² 9/4–5 ml |
| Suh et al. (62)    | 3              | 4 weeks  | 12 weeks| NR | Single spin method<br>• 1100 G–6 min | 0.5-M CaCl² 9/4–5 ml |
| Polster et al. (63) | 3             | 6–9 weeks| 20 weeks| NR | Single spin method<br>• 3500 rpm–10 min | NR/NR |
| Klein et al. (64)  | 3              | 4 weeks  | 12 weeks| Intralesional injection<br>(0.1 ml/cm²) | Single spin method<br>• 1100 G–6 min | NR/NR |

CaCl₂, calcium chloride; FCL, fractional CO₂ laser; G, gravitational force; NR, not reported; PRP, platelet rich plasma; rpm, revolutions per minute.

discoid lupus erythematosus, and central centrifugal cicatricial alopecia) and neutrophilic PCAs (i.e., folliculitis decalvans). Four of the reported efficacious studies used intradermal PRP injection as monotherapy, and patients in two of four studies had concomitant androgenetic alopecia (56, 57, 60, 63).

Quality assessment

Non-randomized studies, particularly case reports and case series, were rated as having a serious or critical risk of bias, mainly due to their inherent potential for confounding and...
Tejapira et al. 10.3389/fmed.2022.1058431

FIGURE 3
Risk of bias of included randomized studies.

Discussion

Increasing evidence emphasizes the efficacy of PRP in treating IMAs. The present systematic review has retrieved a sufficient number of available clinical trials regarding PRP treatment for AA and PCAs to perform a pertinent systematic analysis of results. Our study demonstrates promising results for PRP treatment of patch-type AA either as monotherapy or when compared to intralcalosal TA, topical minoxidil, and LLLT. Moreover, our analysis reveals the efficacy of PRP treatment for PCAs in case reports and small case series. Nevertheless, cumulative evidence is not as convincing for PRP use as standard treatment for AA and PCAs.

PRP therapy is a novel technique comprising autologous plasma preparations with concentrated platelets. Its regenerative effects are gaining momentum in hair loss treatment. PRP is a promising treatment for IMAs because it uses the patient’s healing mechanism, acting on multiple biological targets with minimal immune reaction concerns (27, 29). Nevertheless,
how PRP elicits therapeutic effects in IMAs remains unclear. Based on current evidence, PRP helps regenerate and repair HFs by releasing several key growth factors and cytokines (e.g., PDGF, FGF, EGF, and IGF) that play critical roles in HF stem cell differentiation and proliferation (26, 27). Additionally, PRP impacts the anti-inflammatory effect by downregulating monocyte chemoattractant protein-1, matrix metalloproteinase (MMP)-3, MMP-13, and a disintegrin and metalloproteinase with thrombospondin motifs-5, and immunomodulatory properties by upregulating IL (interleukin)-4, IL-10, IL-13, and TGF-β (65–68). Furthermore, PRP may restore normal skin, prevent fibrosis, and remodel scar tissue (69–72).

Our analysis reveals that PRP has demonstrated favorable results in treating IMAs. The data support the use of PRP as a promising, safe, office-based therapy for hair regrowth in patients with patchy AA; however, variable responses were reported in severe AA types, including AT and AU. Most RCTs demonstrate comparable PRP efficacy to intralesional TA with earlier and more persistent responses (37, 39–41, 47). PRP also showed superior efficacy compared to 5% topical minoxidil and LLLT (34, 43). In contrast to AA, PCAs have fewer studies evaluating the efficacy of PRP, and their treatment endpoint is disease stabilization. Patients in included studies had lymphocytic and neutrophilic scarring alopecias. Case reports and small case series have shown positive clinical outcomes (56–60, 62–64), whereas one case series revealed variable efficacy of PRP treatment (61). However, the use of PRP to treat IMAs is at the initial stage, and several issues remain to be addressed, including efficacy in more severe forms of AA and other subtypes of PCAs, PRP safety, and standard protocols.

PRP is a relatively safe procedure with mild adverse effects, such as tolerable pain, scalp discomfort, burning sensation, and transient erythema. To date, there have been no reports of serious adverse events, such as bleeding and infection. Nevertheless, all included studies highlighted the safety of PRP for IMAs only in short follow-up duration, which could not support its safety appropriately. Notably, contraindications for PRP treatment include hemodynamic instability, coagulation disorders, and infection at the treated site (73).

Although PRP is effective in many studies, its clinical application is complicated by the lack of consensus regarding its preparation and treatment protocol given the number of variables, including equipment, centrifugation forces, number and length of centrifugation, number and interval of treatment sessions, and dosage. Furthermore, evidence supporting long-term maintenance and criteria for treatment candidates is still lacking. The heterogeneity in PRP therapy requires further well-designed studies to overcome these surrounding controversies.

Moreover, it is difficult to determine whether the efficacy of PRP is due to the growth factors and cytokines within the PRP or their production as a result of needle injection-induced trauma since there is currently no solid evidence to support the mechanism of PRP for treating hair disorders speculated by previous studies. There are conflicting results in included studies with a split-scalp design comparing PRP with normal saline solution (36, 42) or TA (33, 40) injections. Previous RCT comparing the efficacy of PRP vs. saline in 26 patients with androgenic alopecia found it an effective treatment; however, the growth factor levels (i.e., PDGF, EGF, and VEGF) did not correlate with clinical improvement (74). The mechanism responsible for improvement following PRP injection remains to be investigated.

This systematic review has some limitations. We included all types of study designs, which contained bias-prone case series and case reports in our analysis. As a result, many of the included studies are of poor quality, particularly those on PCAs. Moreover, many studies have small sample sizes. Lastly, the high heterogeneity between studies, such as diverse PRP preparation, outcome evaluation methods, and disease severity of study populations, prohibits quantitative analysis.

Conclusion

This systematic review reports preliminary evidence that PRP is a promising treatment option for IMAs, particularly in individuals who fail conventional therapies, experience adverse effects, or are contraindicated for other modalities. PRP is a relatively effective treatment for regrowing hairs in AA and alleviating disease progression in PCAs with minimal adverse effects. However, this conclusion is mostly based on limited evidence, including case reports and series and studies with small sample sizes without a proper control group. Moreover, standardized protocols for PRP preparation and treatment remain controversial. Further large-scale, high-quality RCTs with a longer duration of follow-up are crucial to confirm the efficacy and safety of PRP in IMAs. Currently, there is insufficient evidence to support using PRP as standard treatment.

Data availability statement

The original contributions presented in this study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

PS: conceptualization and writing—review and editing. PS, KT, and TY: methodology. PS and NS: validation. KT and TY: formal analysis. KT, TY, and NS: investigation and writing—original draft preparation. NS: data curation. All authors have read and agreed to the published version of the manuscript.
Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.1058431/full#supplementary-material

References

1. Thadanipon K, Suchonwanit P. Measuring patient quality of life following treatment for alopecia. Patient Prefer Adherence. (2021) 15:1601–10. doi: 10.2147/PPA.S282399
2. Leerunyakul K, Suchonwanit P. Asian hair: a review of structures, properties, and distinctive disorders. Clin Cosmet Investig Dermatol. (2020) 13:309–18. doi: 10.2147/ccid.S247390
3. Harncchoowong S, Suchonwanit P. PPARγ agonists and their role in primary cicatricial alopecia. PPAR Res. (2017) 2017:2501248. doi: 10.1155/2017/2501248
4. Iamsomwang W, Leerunyakul K, Suchonwanit P. Finasteride and its potential for the treatment of female pattern hair loss: evidence to date. Drug Des Devel Ther. (2020) 14:951–9. doi: 10.2147/dddt.S204615
5. Suchonwanit P, McMichael AJ. Alopecia in association with malignancy: a review. Am J Clin Dermatol. (2018) 19:853–65. doi: 10.1007/s40257-018-0378-1
6. Paus R, Bullone-Paus S, Bertolini M. Hair follicle immune privilege revisited: the key to alopecia areata management. J Investig Dermatol Symp Proc. (2019) 19:S12–7. doi: 10.1016/j.jids.2017.10.014
7. Rutnin S, Chanprapaph K, Pakornphadungsit K, Leerunyakul K, Vivesiri Y, Srisud T, et al. Variation of hair follicle counts among different scalp areas: a quantitative histophotostudy. Skin Appendage Disord. (2022) 8:24–30. doi: 10.1559/000518434
8. Suchonwanit P, Triamchaisri S, Wittyakornrerk S, Rattanakaemakorn P. Leprosy reaction in thai population: a 20-year retrospective study. Dermatol Res Pract. (2015) 2015:253154. doi: 10.1155/2015/253154
9. Leerunyakul K, Suchonwanit P. Evaluation of hair density and hair diameter in the adult thai population using quantitative trichoscopic analysis. Buimed Res Int. (2020) 2020:2476890. doi: 10.1155/2020/2476890
10. Suchonwanit P, Kositkuljorn C, Poomsoong C. Alopecia areata: an autoimmune disease of multiple players. Immunotargets Ther. (2021) 10:299–312. doi: 10.2147/itt.S626609
11. Chanprapaph K, Mahasaksiri T, Kositkuljorn C, Leerunyakul K, Suchonwanit P. Prevalence and risk factors associated with the occurrence of autoimmune diseases in patients with alopecia areata. J Inflamm (Lond). (2021) 14:4881–91. doi: 10.2147/jifl.S331579
12. Khunkhet S, Vachiramon V, Suchonwanit P. Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians. Int J Dermatol. (2017) 56:161–5. doi: 10.1111/ijd.13453
13. Strazulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. (2018) 78:1–12. doi: 10.1016/j.jaad.2017.04.1141
14. Suchonwanit P, Hector CE, Bin Saif GA, McMichael AJ. Factors affecting the severity of central furcal cicatrical alopecia. Int J Dermatol. (2016) 55:e338–43. doi: 10.1111/ijd.13061
15. Triyankulski K, Srisuwanwattana P, Sripichonjarat T, Suchonwanit P. Fibrising alopecia in a patient pattern: a case report and literature review. Case Rep Dermatol. (2019) 11:297–302. doi: 10.1159/000503681
16. Harries MJ, Paus R. The pathogenesis of primary cicatricial alopecias. Am J Pathol. (2010) 177:2152–62. doi: 10.2353/ajpath.2010.100454
17. Suchonwanit P, Pakornphadungsit K, Leerunyakul K, Khunkhet S, Sripichonjarat T, Rojhirunsakool S. Frontal fibrising alopecia in Asians: a retrospective clinical study. Int J Dermatol. (2020) 59:184–90. doi: 10.1111/ijd.14672
18. Chanprapaph K, Poomsoong C, Kositkuljorn C, Suchonwanit P. Intramuscular corticosteroid therapy in the treatment of alopecia areata: a time-to-event analysis. Drug Des Devel Ther. (2022) 16:107–16. doi: 10.2147/dddt.S41279
19. Mahasaksiri T, Kositkuljorn C, Anuntranse T, Suchonwanit P. Application of topical immunotherapy in the treatment of alopecia areata: a review and update. Drug Des Devel Ther. (2021) 15:1283–98. doi: 10.2147/dddt.S297938
20. Sripichonjarat T, Khunkhet S, Suchonwanit P. A retrospective study of the efficacy and safety of two regimens of diphencylpropyopone in the treatment of recalcitrant alopecia areata. Dermatol Rep. (2017) 9:7399. doi: 10.4081/dr.2017.7399
21. Suchonwanit P, Kositkuljorn C, Mahasaksiri T, Leerunyakul K. A comparison of the efficacy and tolerability of three corticosteroid treatment regimens in patients with alopecia areata. J Dermatolog Treat. (2022) 33:756–61. doi: 10.1080/09546634.2021.1773384
22. Triyankulski K, Suchonwanit P. Role of janus kinase inhibitors in the treatment of alopecia areata. Drug Des Devel Ther. (2018) 12:2323–35. doi: 10.2147/dddt.S172638
23. Rattanakrom T, Suchonwanit P. Are drug treatment strategies really effective against alopecia areata? Expert Opin Pharmacother. (2021) 22:257–60. doi: 10.1080/14656566.2018.1584728
24. Meah N, Wall D, York K, Bhoyrul B, Bokhari L, Sigall DA, et al. The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata. J Am Acad Dermatol. (2020) 83:123–30. doi: 10.1016/j.jaad.2020.03.004
25. Strazulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, et al. Alopecia areata: an appraisal of new treatment approaches and overview of current therapies. J Am Acad Dermatol. (2018) 78:15–24. doi: 10.1016/j.jaad.2017.04.1142
26. Li ZI, Choi H-I, Choi D-K, Sohn K-C, Im M, Seo YJ, et al. Autologous platelet-rich plasma: a potential therapeutic tool for promoting hair growth. Dermatol Surg. (2012) 38:61.
27. Everts P, Onishi K, Jayaram P, Lana JF, Mautner K. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. (2021) 22:7794. doi: 10.3390/ijms2207794
28. Suchonwanit P, Leerunyakul K, Kositkuljorn C. Diagnostic and prognostic values of cutaneous manifestations in COVID-19. Dermatol Ther. (2020) 33:e13650. doi: 10.1111/dth.13650
29. Christgau M, Moder D, Hiller KA, Dada A, Schmalz G, Schmitz G. Growth factors and cytokines in autologous platelet concentrate and their correlation to periodontal regeneration outcomes. J Clin Periodontol. (2006) 33:837–45. doi: 10.1111/j.1600-051X.2006.00911.x
30. Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Bouter L, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. (2019) 366:l4898. doi: 10.1136/bmj.l4898
53. Chihabra G, Verma P. Steroid-resistant alopecia totals in a child successfully treated with oral apremilast and platelet-rich plasma therapy. Dermatol Ther. (2019) 32:e41019. doi: 10.1111/dth.13082

54. Pototschnig H, Maß MT. Successful treatment of alopecia areata barbae with platelet-rich plasma. Cureus. (2020) 12:e7495. doi: 10.7759/cureus.7495

55. Ekelem C, Juhasz M, Yu J, Hooking AM, Couka E, Choi E, et al. Monitoring response to platelet-rich plasma in patients with alopecia areata with optical coherence tomography: a case series. Investig Dermatol Symp Proc. (2020) 28:550–4. doi: 10.1016/j.ijid.2020.05.008

56. Ederaine SA, Kushner CJ, Shapiro J, Lo Sicco KI. Clinical response to adjunctive platelet-rich plasma injections in a patient with alopecia universalis on oral tacrolimus. JAAAD Case Rep. (2022) 20:34–6. doi: 10.1016/j.jdcr.2021.11.019

57. Bolanča Ž, Goren A, Getalđić-Svare B, Vučić M, Štim M. Platelet-rich plasma as a novel treatment for lichen planopilaris. Dermatol Ther. (2016) 29:233–5. doi: 10.1111/dth.12343

58. Jha AK. Platelet-rich plasma for the treatment of lichen planopilaris. J Am Acad Dermatol. (2018) 79:e95–6. doi: 10.1016/j.jaad.2018.05.029

59. Özcan D, Tunçer Vural A, Özen Ö. Platelet-rich plasma for treatment resistant frontal fibrosing alopecia: a case report. Dermatol Ther. (2019) 32:e13072. doi: 10.1111/dth.13072

60. Jha AK. Platelet-rich plasma as an adjunctive treatment in lichen planopilaris. J Am Acad Dermatol. (2019) 80:e90–10. doi: 10.1016/j.jaad.2018.09.013

61. Dina Y, Agha C. Use of platelet-rich plasma in cicatricial alopecia. Dermatol Surg. (2019) 45:979–81. doi: 10.1097/DSS.0000000000001635

62. Swigos K, Yin L, Shaw K, Gutierrez D, Peterson E, Lo Sicco K, et al. Use of platelet-rich plasma in lichen planopilaris and its variants: a retrospective case series demonstrating treatment tolerance without koebnerization. JAAAD Case Rep. (2020) 83:1506–9. doi: 10.1016/j.jdcr.2020.06.026

63. Suh S, Nguyen C, Zhao L, Atanaska Misenkova N. The role of platelet-rich plasma therapy in refractory folliculitis decalvans. JAAAD Case Rep. (2021) 2:85–7. doi: 10.1016/j.jdcr.2021.04.008

64. Polster H, Kushwaha V, Luke J. Platelet-rich plasma for the treatment of scarring alopecia due to discoid lupus erythematosus. J Drugs Dermatol. (2022) 21:309–10. doi: 10.36849/jdd.5953

65. Klein E, Karim M, Kim R, Lo Sicco K, Shapiro J. Reversible hair loss in lichen planopilaris: regrowth with low-dose naltrexone and platelet-rich plasma. J Drugs Dermatol. (2022) 21:671–3. doi: 10.36849/jdd.6810

66. Moussa M, Lajmendes M, Hilal G, El Atai O, Haykal G, Serhal R, et al. Platelet-rich plasma therapy for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. J Drugs Dermatol. (2021) 20:3059513118808773. doi: 10.1177/2059513118808773

67. Sultanovani S, Sultanovani P. Scalp priuritus: review of the pathogenesis, diagnosis, and management. Biomed Res Int. (2019) 2019:5128376. doi: 10.1155/2019/5128376

68. Rattanakamkorn P, Sultanovani P. Scalp priuritus: review of the pathogenesis, diagnosis, and management. Biomed Res Int. (2019) 2019:1268430. doi: 10.1155/2019/1268430

69. Channaprapakh K, Sutharapan T, Sultanovani P. Scalp biological characteristics in males with androgenetic alopecia: a comparative study with healthy controls. Clin Interv Aging. (2016) 11:781–7. doi: 10.2147/cia.S310178

70. Alser OH, Goutsou I. The evidence behind the use of platelet-rich plasma (PRP) in scar management: a literature review. Burns. (2018) 44:2095113188088773. doi: 10.1177/03059188188088773

71. Sultanovani P, Iamsamung W, Leenruyankul K. Topical finasteride for the treatment of androgenetic alopecia in a male patient: a case report. Cureus. (2022) 14:213. doi: 10.7759/cureus.16742

72. Singh HS, Belskaya VA. Platelet-rich plasma augments subcision in atrophic acne scars: a split-face comparative study. J Drugs Dermatol. (2019) 18:90–8. doi: 10.36849/jdd.5953

73. Pomsong C, Sukangananong S, Ratanakasatit Y, Sultanovani P. Epidemiological, clinical, and trichoscopic features of androgenetic alopecia-a retrospective analysis and systematic review. Front Med. (2022) 9:890206. doi: 10.3389/fmed.2022.890206

74. Hesseler MJ, Shyam N. Platelet-rich plasma and its utilities in alopecia: a systematic review. J Dermatol Surg. (2019) 45:90–8. doi: 10.1097/DSS.0000000000001614

75. Ramesh BN, Chakravarty SP, Srinivasan S, Prabhakaran S, Chandrasekar K, et al. Platelet-rich plasma for treatment-resistant alopecia areata: a prospective, randomized, double-blind, placebo-controlled study. J Cutan Aesthet Surg. (2016) 9:150–311. doi: 10.4103/ca.sca_16_19

76. Mehmet C, Bilen O, Akyasa H, Demirkesen O, Saktan K, et al. Platelet-rich plasma for the treatment of scarring alopecia in a patient with hidradenitis suppurativa: a case report. J Drugs Dermatol. (2019) 18:30–5. doi: 10.36849/jdd.13072

77. Elvan G, Nalbantoglu N, Nalbantoglu K, Webli A. Platelet-rich plasma for the treatment of lichen planopilaris. J Drugs Dermatol. (2013) 12:545–9. doi: 10.36849/jdd.2013.0525

78. Suchonwanit P, Triyangkulsri K, Phodyaeng M, Leenruyankul K. Assessing biological and pathological profiles of scalp atheroergic dermatitis in the Thai population. Biomed Res Int. (2019) 2019:5128376. doi: 10.1155/2019/5128376

79. Suchonwanit P, Sultanovani P. Successful treatment of scarring alopecia with oral apremilast and platelet-rich plasma therapy. Cureus. (2020) 12:S50–. doi: 10.7759/cureus.880773

80. Jha AK. Platelet-rich plasma as an adjunctive treatment in lichen planopilaris. J Am Acad Dermatol. (2019) 80:e90–10. doi: 10.1016/j.jaad.2018.09.013

81. Suchonwanit P, Iamsumang W, Leerunyakul K. Topical finasteride for the treatment of male pattern alopecia with platelet-rich plasma: a double-blind, placebo-controlled study. J Drugs Dermatol. (2021) 20:3059513118808773. doi: 10.1177/20595131188088773

82. Sultanovani P, Iamsamung W, Leenruyankul K. Topical finasteride for the treatment of male androgenetic alopecia and female pattern hair loss: a review of the current literature. J Dermatol Treat. (2022) 33:643–8. doi: 10.1080/09546634.2020.1782324

83. Deshmukh NS, Belgumkar VA. Platelet-rich plasma augmentation subcision in atrophic acne scars: a split-face comparative study. J Drugs Dermatol. (2019) 18:90–8. doi: 10.36849/jdd.810554

84. Jha AK. Platelet-rich plasma as an adjunctive treatment in lichen planopilaris. J Am Acad Dermatol. (2019) 80:e90–10. doi: 10.1016/j.jaad.2018.09.013